An Original Therapeutic Approach: Immunotherapy
All tests for years with conventional treatments, to improve the rate of relapse, ended in failure. A totally new approach to treatment is a therapeutic vaccine that would prevent recurrence after initial successful treatment. The principle of this immunotherapeutic approach based on injection of a molecule called Abagovomab patients suffering from ovarian cancer. The vaccine stimulates the immune system of women so that it selects and destroy tumor cells to prevent tumor recurrence. Focus on principle rather conventional Vaccine:
- This molecule is an antigen designed to resemble the antigen CA125, a protein found in large quantities on the surface of tumor cells in ovarian cancer. The Abagovomab is nevertheless sufficiently different from the CA 125 in order to induce, once injected, the immune response of the patient against him, and thereby against the CA125 antigen, very close.
- A classic immune response occurs when: the antibodies induced by the patient specifically recognize antigens CA125 in the tumor cells and bind to, leading, ideally, the elimination of tumor cells carrying the antigen, now recognized as foreign. If the system works in practice is therefore the patient herself who synthesizes antibodies eradicating the tumor. Thanks to the vaccine based Abagovomab, the immune system should be able to recognize and attack tumor cells that have the protein CA125.

This could bring hope that the immune system starts to fight all residual tumor cells and that they succeed and to prevent any recurrence of the disease. “The medical community has great hopes on immunotherapy. She hopes that it will, finally, a treatment that will prevent recurrence often fatal cancer of the ovary.

